| Objective:To evaluate the efficacy and safety of S-l combined platinum or oxaliplatin in treatment of advanced gastric cancerMethods:According to Cochrane Collaboration criteria, we developed comprehensive search strategies to collect all randomized controlled trials about the S-1 combined with cisplatin or oxaliplatin for advanced gastric cancer. Primary endpoint was overall survival,secondary endpoint were the overall Response Rate,Time to Treatment Failure,Progression-Free Survival,Time to radiologic Progression Time To Symptomatic Progression Disease-Free Survival and safety. CENTRAL (the Cochrane central register of controlled trials,1970-2010.1),EMBASE(1974-2010.01.01),PUBMED (1966-2010.01.01),CBM,CNKI,VIP,WANFANG DATA were searched electronically. Relevant journals and conference proceedings were also hand searched. The quality of included studies was assessed according to the criteria recommended by the Cochrane Handbook 5.0 for systematic reviews of Interventions, statistical analyses were performed with Stata 9.0.Results:10 studies were included, and 1840 cases were included. Meta analysis showed that the RR of S-1/cisplatin or oxaliplatin group was superior to controlled group (OR= 0.274,95% CI [0.188-0.398]) for advanced gastric cancer in China. S-1/cisplatin or oxaliplatin group did not result in a significant survival improvement(HR= 0.74,95% CI 0.44-1.27). Compared with the control group, S-1/cisplatin or oxaliplatin group was no disadvantage in safety.Conclusion:S-1/cisplatin or oxaliplatin regimen may improve response rate and well tolerated in Chinese patients with advanced gastric cancer.however,S-1/cisplatin did not result in a significant efficacy and safety improvement in Europe and the United States patients with advanced gastric cancer. Further studies are needed to clearly factors which affecting the efficacy of S-1. |
PDF Full Text Request